accountwhose effectiveness is very comparable to Cerezyme,' said Dr. Geoffrey McDonough, senior vice president of Genzyme's Lysosomal Storage Diseases business. 'It could change the landscape for Gaucher.' Gaucher affects fewer than 10,000 people worldwide and...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Genzyme's oral Gaucher therapy meets goal of trial
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account